# Lilly France S.A.S. – FDA Inspection, Apr 4, 2017

Source: https://www.keypedia.com/records/fda_inspections/lilly-france-sas/e5ccc457-4508-4a84-a212-24a4fa072cb5
Source feed: FDA_Inspections

> FDA inspection 1020863 of Lilly France S.A.S., April 04, 2017. Classification: Voluntary Action Indicated (VAI). Form 483 issued. 8 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1020863
- Company Name: Lilly France S.A.S.
- Inspection Date: 2017-04-04
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1299456 - 2023-09-29
- FDA Inspection 1180181 - 2021-01-15
- FDA Inspection 1117961 - 2020-01-16
- [FDA Inspection 1081382 - 2019-02-19](https://www.keypedia.com/records/fda_inspections/lilly-france-sas/107930e4-af02-49fc-acbe-092ab003f224)
- [FDA Inspection 1063854 - 2018-08-28](https://www.keypedia.com/records/fda_inspections/lilly-france-sas/f327e9ea-160b-4d12-8602-054ba10008d1)

## Related Officers

- Issuing Officer
- [FDA Associated Person](https://www.keypedia.com/people/zachery-l-miller/e7ff2001-1e81-4483-9e9b-288b7e92c719)

Company: https://www.keypedia.com/companies/lilly-france-sas/27fa7368-5fb0-48b1-b161-5729c7bfa061

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c